新泽西州李堡/以色列雷霍沃特-2017年8月25日-Kedrion Biopharma和Kamada有限公司（纳斯达克和塔斯社：KMDA）两家领先的人类源性蛋白质治疗公司今天宣布，Kedrab™[狂犬病免疫球蛋白（人）]已经获得美国食品和药物管理局（FDA）的被动批准，在接触狂犬病或可能狂犬病动物后立即给予狂犬病感染后的短暂暴露预防。凯德拉布应与一个完整的狂犬病疫苗疗程同时使用。狂犬病是一种危及生命的疾病，每年影响美国大约40000人，代表每年1亿美元的市场机会。Kedrab将于2018年初在美国上市。

在FDA批准Kedrab之前，美国医疗专业人员只有两种人类狂犬病免疫球蛋白（Human Rabies Immune Globin，HRIG）治疗方案可供选择，以防止可能接触致命病毒的人患上狂犬病。kedrab是一种人血浆衍生免疫球蛋白，近年来进入狂犬病市场，其供应量一直不稳定。

Kedrion公司总裁兼首席执行官保罗•马库奇（Paolo Marcucci）表示：“FDA对Kedrab的批准，标志着随着我们在美国业务的不断增长，Kedrion生物制药公司的发展具有激动人心的重要里程碑意义。”“Kedrab的批准是Kedrion Biopharma在其整个临床开发过程中以及在美国商业化过程中发挥作用的第一个产品。狂犬病是一种致命但完全可以预防的疾病，我们很高兴为医生提供另一种安全有效的选择。正如KeDron BiopHMA公司是世界领先的高滴度狂犬病血浆供应商之一，我们很有可能最大化该产品的潜力，我们期待着与KAMADA合作，在美国推出KedRAB。

Kamada首席执行官Amir London说：“Kamada的这一重大成就代表了FDA对该公司的第二次批准。”“我们很自豪，我们独特和先进的免疫球蛋白纯化技术被用于凯德拉布的开发，并期待凯德拉布生物制药公司成功推出该产品。bla的批准也可以作为在其他国家注册的依据。这种治疗在美国代表着每年超过1亿美元的市场机会，我们期望在其中占有重要的市场份额。此外，这有可能成为我们公司的高利润产品。Kedrab的有意义的销售预计将在2018年，即其推出的第一个完整年度内大幅增长。本产品的收入不包括在我们2017年总收入达到1亿美元的指导中。”

自2006年以来，Kamada一直在美国以外的许多地区销售品牌为Kamrab™的HRIG产品。迄今为止，Kamada已售出140多万瓶Kamrab，展示了该产品的重要临床经验。根据Kedrion Biopharma和Kamada之间的临床开发和营销协议，在收到FDA的营销批准后，Kamada持有Kedrab的许可证，Kedrion Biopharma拥有在美国将产品商业化的独家权利。

经Kedrab批准，Kedrion Biopharma扩大了免疫球蛋白产品组合，包括Rhogam®和Gammaked™。

关于凯德拉布™

KedRAB [狂犬病免疫球蛋白（人类）]是一种人类狂犬病免疫球蛋白（HRIG），用于狂犬病感染的被动、暂时性暴露后预防（PEP），当与狂犬病或可能狂犬病动物接触后及时给予。KedRAB应与狂犬病疫苗的全过程同时施用。

重要安全信息

能够记录以前完整的狂犬病暴露前预防或完全暴露后预防的患者应只接种没有KedRAB的增强型狂犬病疫苗，因为KedRAB可能会干扰对疫苗的过敏反应。

KedRAB不应注射到血管中，因为存在严重过敏或过敏反应的风险，包括过敏性休克。

在服用人体免疫球蛋白制剂后有先前全身过敏反应史的患者应监测超敏反应。

KedRAB 包含少量 IgA。缺乏IgA的患者有开发IgA抗体的潜力，在服用含有IgA的血液成分后可能有过敏反应。

在KedRAB给政治疗后，应至少24小时监测血栓形成或血栓并发症风险增加的患者。

溶血可能发生在接受免疫球蛋白产品的患者中，特别是那些被确定为风险增加的患者。

KedRAB给政可能干扰对活衰减病毒疫苗的免疫反应的发展。

在KedRAB给药后，患者血液中各种被动转移抗体的短暂上升可能导致血清学检测的误导性阳性结果。

KedRAB来自人类血浆;因此，KedRAB管理可能传播传染性病原体。

在临床试验中，使用KedRAB治疗的受试者最常见的不良反应是注射部位疼痛、头痛、肌肉疼痛和上呼吸道感染。

KedRAB (rabies immunoglobulin human) Injection

Date of Approval: August 23, 2017
Company: Kamada Ltd. and Kedrion S.p.A.
Treatment for: Rabies Prophylaxis

KedRAB [rabies immunoglobulin (human)] is a human plasma derived anti-rabies immunoglobulin indicated for post-exposure prophylaxis (PEP) of rabies infection.

KEDRAB
Rabies Immune Globulin (human)
Solution for Intramuscular Injection

DESCRIPTION

KEDRAB is a sterile, non-pyrogenic aqueous solution of anti-rabies immunoglobulin (≥95% protein as IgG). The product is stabilized with 0.3 M glycine and has a pH of 5.5 ± 0.5. It does not contain preservatives and the vial stopper is not made with natural rubber latex. KEDRAB is a clear to opalescent liquid.

KEDRAB is prepared from human plasma from donors hyper-immunized with rabies vaccine. Individual plasma units are tested using FDA-licensed serologic assays for hepatitis B surface antigen (HBsAg) and for antibodies to hepatitis C virus (HCV) and human immunodeficiency virus types 1 and 2 (HIV-1/2), as well as by FDA-licensed Nucleic Acid Testing (NAT) for hepatitis B virus (HBV), HCV and HIV-1. Each plasma unit must be non-reactive (negative) in all tests. Plasma is also tested by in-process NAT procedures for HAV and parvovirus B19. Each plasma unit must be non-reactive to HAV, while the limit in the manufacturing pool is set not to exceed 104 IU per mL for parvovirus B19.

To reduce the risk of viral transmission further, the manufacturing process for KEDRAB includes three steps specifically designed to remove or inactivate viruses. The first of these is solvent/detergent (S/D) treatment with a mixture of tri-(n-butyl) phosphate (TnBP) and Octynoxol 9, which inactivates enveloped viral agents such as HIV, HBV and HCV. The second and third are heat-treatment (pasteurization) steps, which can inactivate both enveloped and non–enveloped viruses, and a nanofiltration (NF) step which removes viruses on the PRVbasis of size. The effectiveness of the S/D treatment, pasteurization and nanofiltration procedures for reducing viral content has been assessed using a series of viruses with a range of physico-chemical characteristics. The results of the viral challenge studies are summarized in Table 2.

Table 2: Log10 Virus Reduction during Manufacture of KEDRAB

Indications

INDICATIONS

KEDRAB is a human rabies immunoglobulin (HRIG) indicated for passive, transient post-exposure prophylaxis (PEP) of rabies infection, when given immediately after contact with a rabid or possibly rabid animal. KEDRAB should be administered concurrently with a full course of rabies vaccine.

· Do not administer additional (repeat) doses of KEDRAB once vaccine treatment has been initiated, since this may interfere with the immune response to the rabies vaccine.

· Do not administer KEDRAB to patients with a history of a complete pre-exposure or post-exposure vaccination regimen and confirmed adequate rabies antibody titer.1

· Do not mix with the rabies vaccine or administer in the same syringe with the rabies vaccine.

· Do not administer into the same anatomical site(s) as rabies vaccine.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. If either of these conditions exists, DO NOT use KEDRAB; discard the vial.

Dosage

DOSAGE AND ADMINISTRATION

· For wound infiltration and intramuscular use. Do not administer intravenously.

Local Treatment Of Wounds Prior To KEDRAB Administration

The World Health Organization (WHO) and the U.S. Public Health Service Advisory Committee on Immunization Practices (ACIP) have outlined recommendations for passive and active immunization after exposure to an animal suspected of having rabies.1,2 Immediate and thorough cleansing of all bite wounds and scratches with soap and water is an important component of post-exposure prophylaxis (PEP). A virucidal agent (e.g., povidone-iodine solution) should be used to irrigate the wounds.

Tetanus prophylaxis and measures to control bacterial infection should be given if medically indicated.

Dosage

Post-exposure prophylaxis consists of a single dose of KEDRAB and a full course of rabies vaccine. The recommended dose of KEDRAB is 20 IU/kg body weight, given at the time of the first vaccine dose. KEDRAB and the first dose of rabies vaccine should be given as soon as possible after exposure, as delays are potentially lethal. However, should a delay occur, KEDRAB should be administered at any time up to and including seven days after the first dose of vaccine. The rabies vaccine should be given according to the manufacturer’s instructions.

No more than the recommended dose of KEDRAB should be given because KEDRAB partially suppresses active antibody production following vaccination. For the same reason, additional doses of KEDRAB should not be given, even if the antibody response to vaccination is delayed.

Administration

· When the bite site is known and infiltration at the bite site is feasible:

o Infiltrate as much of the dose as possible into and around any detectable bite wounds. Inject any remaining volume intramuscularly into the upper arm deltoid region or, in small children, into the anterolateral aspect of the thigh. Administer the remaining KEDRAB at site(s) distant from the site of the rabies vaccine.

· Avoid administration into the gluteal region, where absorbance is unpredictable (unless the exposure site is in the gluteal region):

· When the bite site is unknown or indeterminate (undetectable) or if infiltration is difficult at the bite site (e.g., lips, fingers, knee), administer the full KEDRAB dose by the intramuscular route at a site distant from the site of rabies vaccination.

· If a large intramuscular volume is required (>2 mL for children or >5 mL for adults), administer the total volume in divided doses at different sites.

· If intramuscular administration is contraindicated (e.g., in patients with uncorrectable bleeding disorders), administer KEDRAB subcutaneously. However, note that there are no clinical efficacy data to support administration of KEDRAB by the subcutaneous route.

Further Information On Rabies Post-Exposure Prophylaxis

Consult local or state public health officials if questions arise about the need for rabies prophylaxis.

HOW SUPPLIED

Dosage Forms And Strengths

KEDRAB is supplied in single-use vials containing 2 mL or 10 mL of ready-to-use solution with a nominal potency of 150 IU/mL.

The 2-mL vial contains a total of 300 IU and the 10-mL vial contains a total of 1,500 IU. The final product is assayed with human rabies immunoglobulin reference standard that is calibrated against the WHO International Standard.

Storage And Handling

· Each carton of KEDRAB contains a single-use vial containing 2 mL or 10 mL of ready-to-use solution with a potency of 150 IU/mL.

· The 2-mL vial contains a total of 300 IU which is sufficient for a child weighing 15 kg (33 lb). (NDC 76125-150-02). The 10-mL vial contains a total of 1500 IU which is sufficient for an adult weighing 75 kg (165 lb). (NDC 76125-150-10)

· Store KEDRAB at 2-8 °C (36-46 °F). Do not freeze.

· Keep vial in carton until use.

· KEDRAB may be stored at room temperatures not exceeding 25 °C (77 °F) for up to one month.

· Use within one month after removal from refrigeration, Do not return to refrigeration.

· Do not use after the expiration date printed on the label.

REFERENCES

1. Human rabies prevention—United States, 2008: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2008;57 (No. RR-3).

2. Use of a Reduced (4-Dose) Vaccine schedule for postexposure prophylaxis to prevent human rabies: Recommendations of the Advisory Committee on Immunization Practices. MMWR 2010;59 (No. RR-2).

3. WHO 2013, Expert Consultation on Rabies. Second Report. Geneva: WHO Press. Technical Report Series (No. 982).

Distributed by: Kedrion Biopharma Inc. Parker Plaza, 400 Kelby St. Fort Lee, NJ 07024. Revised: n/a

Side Effects

SIDE EFFECTS

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates of adverse reactions in clinical trials of another drug and may not reflect the rates observed in clinical practice.

KEDRAB was evaluated in three single-center, controlled clinical trials. Subjects in the clinical studies of KEDRAB were healthy adults, primarily white and ranged in age from 18 to 72 years. A total of 160 subjects were treated in these three studies, including 91 subjects who received single intramuscular doses of KEDRAB (20 IU/kg) with or without rabies vaccine.

Table 1 summarizes adverse events (assessed by the investigator as related or unrelated to study treatment) occurring in >3% of subjects in the clinical trials of KEDRAB. The most frequent adverse events in the KEDRAB group (>6%) were injection site pain, headache, muscle pain, and upper respiratory tract infection (Table 1).

Table 1: Adverse Events Occurring in >3% of Subjects in All Studies Combined

Less common adverse events were joint pain, dizziness, fatigue, abdominal pain, blood in urine, nausea, feeling faint, bruising, sunburn, and white blood cells in urine.

Drug Interactions

DRUG INTERACTIONS

· Do not administer additional (repeat) doses of KEDRAB once vaccination has been initiated, since additional doses of KEDRAB may interfere with the immune response to the vaccine.

· Do not administer KEDRAB into the same anatomical site(s) as rabies vaccine.

· KEDRAB contains other antibodies that may interfere with the response to live vaccines such as measles, mumps, polio or rubella. Avoid immunization with live virus vaccines within 3 months after KEDRAB administration, or in the case of measles vaccine, within 4 months after KEDRAB administration [see WARNINGS AND PRECAUTIONS].

Warnings & Precautions

WARNINGS

Included as part of the "PRECAUTIONS" Section

PRECAUTIONS

Previous Rabies Vaccination

· Patients who can document previous complete rabies pre-exposure prophylaxis or complete post-exposure prophylaxis should only receive a booster rabies vaccine without KEDRAB, because KEDRAB may interfere with the anamnestic response to the vaccine (ACIP)1.

Anaphylactic Shock

· KEDRAB should not be injected into a blood vessel because of the risk of severe allergic or hypersensitivity reactions, including anaphylactic shock. KEDRAB can induce a fall in blood pressure associated with an anaphylactic reaction, even in patients who tolerated previous treatment with human immunoglobulin.

· Discontinue KEDRAB injection immediately if there is an allergic or anaphylactic type reaction. In case of shock, implement standard medical treatment. Epinephrine should be available for treatment of acute anaphylactic symptoms.

Hypersensitivity

· Patients with a history of prior systemic allergic reactions following administration of human immune globulin preparations should be monitored for hypersensitivity.

· KEDRAB contains a small quantity of IgA. Patients who are deficient in IgA have the potential to develop IgA antibodies and may have anaphylactic reactions following administration of blood components containing IgA. The healthcare provider should assess the risks of this reaction against the benefits of administering KEDRAB.

Thrombosis

· Patients at increased risk of thrombosis or thrombotic complications should be monitored for at least 24 hours after KEDRAB administration.

· Patients at increased risk of thrombosis include patients with acquired or hereditary hypercoagulable states, prolonged immobilization, in-dwelling vascular catheters, advanced age, estrogen use, a history of venous or arterial thrombosis, cardiovascular risk factors (including history of atherosclerosis and/or impaired cardiac output), and hyperviscosity syndromes (including cryoglobulinemias, fasting chylomicronemia and/or high triglyceride levels, and monoclonal gammopathies).

· Consider measurement of baseline blood viscosity in patients at risk for hyperviscosity.

Hemolysis

· Hemolysis may occur in patients receiving immune globulin products, particularly those who are determined to be at increased risk. Patients at increased risk include those with non-O blood group types, those with underlying associated inflammatory conditions, and those receiving high cumulative doses of immune globulins over the course of several days.

· Clinical symptoms and signs of hemolysis include fever, chills and dark urine. If any of these occur, perform appropriate laboratory testing and administer medical therapy as indicated.

Live Attenuated Virus Vaccines

· KEDRAB administration may interfere with the development of an immune response to live attenuated virus vaccines.

o Avoid immunization with measles vaccine within 4 months after KEDRAB administration.

o Avoid immunization with other live attenuated virus vaccines within 3 months after KEDRAB administration.

Interference With Serologic Testing

· A transient rise of the various passively transferred antibodies in the patient’s blood may result in misleading positive results of serologic tests after KEDRAB administration.

· Passive transmission of antibodies to erythrocyte antigens, e.g., A, B, and D, may interfere with serologic tests for red cell antibodies such as the antiglobulin test (Coombs’ test).

Transmissible Infectious Agents

· KEDRAB is derived from human plasma; therefore, the potential exists that KEDRAB administration may transmit infectious agents such as viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent.

· The risk of transmitting an infectious agent has been minimized by

o Screening plasma donors for prior exposure to certain viruses

o Testing for certain viral infections

o Inactivating and removing certain viruses during the manufacturing process [see DESCRIPTION].

Despite these measures, KEDRAB administration can still potentially transmit infectious diseases. There is also the possibility that unknown infectious agents may be present in KEDRAB.

Any infection considered to have possibly been transmitted by this product should be reported by the physician or other healthcare provider to Kedrion Biopharma Inc. Customer Service (1-855-353-7466) or FDA at 1-800-FDA-1088.

Use In Specific Populations

Pregnancy

Risk Summary

KEDRAB has not been studied in pregnant women. Therefore, the risk of major birth defects and miscarriage in pregnant women who are exposed to KEDRAB is unknown. Animal developmental or reproduction toxicity studies have not been conducted with KEDRAB. It is not known whether KEDRAB can cause harm to the fetus when administered to a pregnant woman or whether KEDRAB can affect reproductive capacity. In the U.S. general population, the estimated background of major birth defects occurs in 2-4% of the general population and miscarriage occurs in 15-20% of clinically recognized pregnancies.

Lactation

Risk Summary

There is no information regarding the presence of KEDRAB in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for KEDRAB and any potential adverse effects on the breastfed infant from KEDRAB or from the underlying maternal condition.

Pediatric Use

The safety and effectiveness of KEDRAB in the pediatric population have not been established.

Geriatric Use

Clinical studies of KEDRAB did not include sufficient numbers of subjects aged 65 years and over to determine whether they respond differently from younger subjects. Clinical experience with HRIG products has not identified differences in effectiveness between elderly and younger patients (ACIP)1.

Clinical Pharmacology

CLINICAL PHARMACOLOGY

Mechanism Of Action

Rabies is a zoonotic disease caused by RNA viruses in the family Rhabdoviridae, genus Lyssavirus. Virus is typically present in the saliva of rabid mammals and is transmitted primarily through a bite. KEDRAB is infiltrated into the inoculation site (i.e., at the beginning of anti-rabies PEP) to previously unvaccinated persons, to provide immediate passive rabies virus neutralizing antibody protection until the patient’s immune system responds to vaccination by actively producing antibodies.

Pharmacodynamics

A protective threshold for rabies virus neutralizing activity (RVNA) has never been established. However, the WHO has generally accepted a RVNA of at least 0.5 IU/mL measured 14 days after initiation of PEP as protective. By comparison, the ACIP recommends complete neutralization of rabies virus at a 1:5 serum dilution by a rapid fluorescent focus inhibition test (RFFIT) from 1 to 2 weeks after prophylaxis; this corresponds to RVNA ~0.1-0.2 IU/mL. In support of these recommendations, there has been almost no documented clinical disease when the current rabies PEP regimen is administered appropriately (ACIP) 1.

KEDRAB has the potential to attenuate the patient’s immune response to rabies vaccine. This was evaluated in a double-blind, randomized study where 16 healthy subjects were administered either KEDRAB (20 IU/kg IM) or saline placebo followed by three doses of a rabies vaccine (Table 3). Lower RVNA levels were seen in the KEDRAB + vaccine group compared to the placebo + vaccine group at all time-points beginning on Day 14, confirming that KEDRAB interferes with the host immune response to rabies vaccine.

Pharmacokinetics

A randomized, single-dose, two-period, two-treatment, two-sequence, double-blind, crossover study assessed the pharmacokinetics of KEDRAB. Twenty-six healthy volunteer subjects were randomized to receive a single IM injection of 20 IU/kg HRIG on two separate occasions (KEDRAB or Comparator HRIG). Subjects received the second treatment (A or B) following the 42-day test period and a 21-day washout period. Single dose IM injection of KEDRAB resulted in maximum plasma RVNA levels of 0.25 IU/mL. The median Tmax was 7 days (range: 3 – 14 days). The elimination half-life was approximately 17.9 days. A statistical analysis of the pharmacokinetic parameters showed that KEDRAB was not bioequivalent to the Comparator HRIG (Table 3).

Table 3: Statistical Analysis of Rabies Virus Neutralizing Antibody Pharmacokinetic Parameters - Crossover Study of KEDRAB

A plot of plasma rabies virus neutralizing antibody titer concentration versus time (Figure 1) demonstrated that, in both treatment groups, plasma rabies virus neutralizing antibody concentrations declined in a biphasic manner after the absorption phase was complete.

Figure 1: Plasma HRIG Concentrations [Mean (±SD)] at Scheduled PK Sampling Days (Semi-log Scale), Phase 2/3 Study, Pharmacokinetic Analysis

Additionally, a prospective, randomized, double-blind, non-inferiority, study evaluated the pharmacokinetics, safety and effectiveness of simulated post-exposure prophylaxis with KEDRAB with co-administration of active rabies vaccine in 118 healthy subjects. Subjects were randomized into two treatment groups (59 per treatment group) to receive intramuscular KEDRAB or comparator HRIG at a dose of 20 IU/kg on Day 0, and rabies vaccine on Days 0, 3, 7, 14 and 28. The peak plasma RVNA was 71.9 IU/mL and 53.9 IU/mL for KEDRAB and comparator HRIG respectively. For both treatment groups, the median Tmax was 14 days (range: 14 – 49 days). The half-lives were 48.6 hours and 52.7 hours for KEDRAB and comparator HRIG respectively.

Bioequivalent assessment showed that KEDRAB was not bioequivalent to the comparator HRIG when co-administered with a five-dose rabies vaccine regimen (Table 4). Furthermore, the RVNA on Day 3 was lower in the KEDRAB with rabies vaccine group relative to the Comparator HRIG with vaccine group (0.188±0.051 vs 0.229±0.054, P=0.0005). However, these pharmacokinetic differences are not expected to affect clinical outcomes.

Table 4: Pharmacokinetic Comparison of Rabies Virus Neutralizing Antibody between KEDRAB and a Comparator HRIG Administered with Rabies Vaccine

Please see Clinical Studies section for clinical efficacy.

Animal Toxicology And/Or Pharmacology

Intramuscular administration of a single dose of KEDRAB to rats at 60 and 120 IU/kg (3-fold and 6-fold higher than the recommended human dose of 20 IU/kg), did not result in any signs of toxicity.

Clinical Studies

The efficacy of KEDRAB administered concurrently with rabies vaccine was studied in a single-center, randomized, comparator HRIG-controlled clinical study. Study subjects were healthy adults 18 to 72 years of age who were without significant acute or chronic illness. A total of 118 subjects (59 per treatment group) received intramuscular KEDRAB or comparator HRIG at a dose of 20 IU/kg on Day 0, and rabies vaccine on Days 0, 3, 7, 14 and 28. The mean age of study subjects was 45 years; subjects were, predominantly white (93%), and 64% were women. The efficacy variable was RVNA, as assessed by RFFIT, on Day 14. Efficacy analyses were performed on the As-Treated Population, which comprised the 116 study subjects who received KEDRAB or comparator HRIG and at least 3 of the 5 doses of rabies vaccine before Day 14.

Efficacy, considered when RVNA titer is 0.5 IU/mL or higher on Day 14 (as established by the WHO), was met by 56/57 subjects (98.2%) in the KEDRAB group and 59/59 subjects in the comparator HRIG group (Table 5). The lower limit of the 90% CI was greater than the pre-specified non-inferiority margin of -10%; thus, KEDRAB was non-inferior to comparator HRIG.

Table 5: Subjects with Geometric Mean RVNA ≥0.5 IU/mL on Day 14 (As-Treated Population)

Additional efficacy analyses included pharmacokinetics [see CLINICAL PHARMACOLOGY].

Medication Guide

PATIENT INFORMATION

The KEDRAB manufacturing process includes three valid and effective viral elimination steps. In addition, the process allows the removal of thrombogenic activity.

Inform patients that KEDRAB is made from human plasma and may contain infectious agents that can cause disease (e.g., viruses and, theoretically, the CJD agent). Explain that the risk of KEDRAB transmitting an infectious agent has been reduced by screening the plasma donors, by testing the donated plasma for certain virus infections, and by a process demonstrated to inactivate and/or remove certain viruses during manufacturing [see WARNINGS AND PRECAUTIONS]. Inform patients of symptoms of a possible viral infection, including headache, fever, nausea, vomiting, weakness, malaise, diarrhea, or, in the case of hepatitis, jaundice.